Market Overview:
The global hemophilia A drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hemophilia A, rising awareness about available treatments, and growing demand for gene therapies. Hemophilia A is a rare bleeding disorder caused by lack of clotting factor VIII (FVIII) in the blood. It results in excessive bleeding, which can cause serious health problems and even death if not treated properly. There are three main types of hemophilia: hemophilia A, B, and C. Hemophilia A is the most common type and accounts for approximately 80% of all cases worldwide. The key players operating in this market are Bayer AG (Germany), Biogen Inc.(US), Novo Nordisk AS (Denmark), Pfizer Inc.(US), Roche Holding AG (Switzerland), Sanofi SA(France)and Shire Plc.(UK).
Product Definition:
Hemophilia A Drug is used to prevent and treat bleeding in people with hemophilia A. Hemophilia A is a disorder that makes it difficult for the blood to clot.
ATXF-8117:
ATXF-8117 is a novel oral drug developed by BioMarin for the treatment of hereditary factor X deficiency (FXD) caused in males by a lack of an appropriate protein. The drug was granted Orphan Drug Designation and Fast Track Designation for the treatment of hemophilia A and B, respectively, by U.S. FDA in 2016 and 2017.
BAY-1093884:
BAY-1093884 is a novel oral drug developed by Bioasis Technologies for the treatment of hereditary factor X deficiency (FXD). It is currently in phase II clinical trials and has shown encouraging results. The product has also received Orphan Drug Designation from FDA for the treatment of FXD.
Application Insights:
Based on application, the market is segmented into hospital-based, ASCs and clinics. The ASCs segment dominated the overall industry in terms of revenue in 2017 owing to factors such as a high prevalence of hemophilia among male infants and adult patients suffering from bleeding disorders. Furthermore, rising awareness about availability of affordable treatment options for hemophilia will boost product demand over the forecast period.
The hospital-based segment is expected to witness significant growth during the study period due to increasing prevalence of Bleeding Disorders Association (ADA) certified centers across North America and Europe coupled with growing adoption of recombinant factor VIIa (rFVIIa) therapy for treatment purposes. In addition, presence of key players involved in R&D & manufacturing process development along with strong support from government agencies will further propel industry growth over the coming years. For instance, Pfizer Inc.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and rising prevalence of bleeding disorders are some factors responsible for its growth. In addition, increasing use of factor VIII and IX concentrates is expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments as well as private organizations coupled with growing awareness about hemophilia care in developing countries such as India and China. Furthermore, availability of generic drugs at low prices due to economies of scale offered by large pharmaceutical companies will also boost revenue generation in this region over the next eight years time frame.
In addition, high prevalence rate for coagulation disorders among people from Latin American countries such as Brazil is also driving factors that contribute toward overall revenue generation in this region’s Hemophilia A Drug Market Report 2018-19).
Growth Factors:
- Increasing incidence of Hemophilia A Drug
- Growing demand for better treatment options for Hemophilia A Drug patients
- Rising awareness about available treatments for Hemophilia A Drug
- Technological advancements in the field of hemophilia treatment
- Availability of government funding and support programs for hemophilia patients
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemophilia A Drug Market Research Report
By Type
ATXF-8117, BAY-1093884, BIVV-001, BS-027125, Concizumab, CSL-689, Others
By Application
Clinic, Hospital, ASCs
By Companies
Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, EpiVax Inc, Expression Therapeutics LLC, Bayer AG, Idogen AB, Immusoft Corp, LFB SA, mAbxience SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
122
Number of Tables & Figures
86
Customization Available
Yes, the report can be customized as per your need.
Global Hemophilia A Drug Market Report Segments:
The global Hemophilia A Drug market is segmented on the basis of:
Types
ATXF-8117, BAY-1093884, BIVV-001, BS-027125, Concizumab, CSL-689, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, ASCs
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- BioMarin Pharmaceutical Inc
- Bioverativ Inc
- Catalyst Biosciences Inc
- Chugai Pharmaceutical Co Ltd
- CSL Ltd
- DBV Technologies SA
- Dimension Therapeutics Inc
- EpiVax Inc
- Expression Therapeutics LLC
- Bayer AG
- Idogen AB
- Immusoft Corp
- LFB SA
- mAbxience SA
Highlights of The Hemophilia A Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ATXF-8117
- BAY-1093884
- BIVV-001
- BS-027125
- Concizumab
- CSL-689
- Others
- By Application:
- Clinic
- Hospital
- ASCs
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemophilia A Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemophilia A is a rare blood disorder caused by a deficiency of factor VIII. This protein helps to form the blood clots that can prevent death in people with hemophilia A. Hemophilia A drugs help to replace the missing factor VIII and help prevent bleeding episodes.
Some of the major players in the hemophilia a drug market are Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, EpiVax Inc, Expression Therapeutics LLC, Bayer AG, Idogen AB, Immusoft Corp, LFB SA, mAbxience SA.
The hemophilia a drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hemophilia A Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hemophilia A Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hemophilia A Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hemophilia A Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hemophilia A Drug Market Size & Forecast, 2020-2028
4.5.1 Hemophilia A Drug Market Size and Y-o-Y Growth
4.5.2 Hemophilia A Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ATXF-8117
5.2.2 BAY-1093884
5.2.3 BIVV-001
5.2.4 BS-027125
5.2.5 Concizumab
5.2.6 CSL-689
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 ASCs
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hemophilia A Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hemophilia A Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ATXF-8117
9.6.2 BAY-1093884
9.6.3 BIVV-001
9.6.4 BS-027125
9.6.5 Concizumab
9.6.6 CSL-689
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 ASCs
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ATXF-8117
10.6.2 BAY-1093884
10.6.3 BIVV-001
10.6.4 BS-027125
10.6.5 Concizumab
10.6.6 CSL-689
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 ASCs
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ATXF-8117
11.6.2 BAY-1093884
11.6.3 BIVV-001
11.6.4 BS-027125
11.6.5 Concizumab
11.6.6 CSL-689
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 ASCs
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ATXF-8117
12.6.2 BAY-1093884
12.6.3 BIVV-001
12.6.4 BS-027125
12.6.5 Concizumab
12.6.6 CSL-689
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 ASCs
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ATXF-8117
13.6.2 BAY-1093884
13.6.3 BIVV-001
13.6.4 BS-027125
13.6.5 Concizumab
13.6.6 CSL-689
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 ASCs
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hemophilia A Drug Market: Competitive Dashboard
14.2 Global Hemophilia A Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer AG
14.3.2 BioMarin Pharmaceutical Inc
14.3.3 Bioverativ Inc
14.3.4 Catalyst Biosciences Inc
14.3.5 Chugai Pharmaceutical Co Ltd
14.3.6 CSL Ltd
14.3.7 DBV Technologies SA
14.3.8 Dimension Therapeutics Inc
14.3.9 EpiVax Inc
14.3.10 Expression Therapeutics LLC
14.3.11 Bayer AG
14.3.12 Idogen AB
14.3.13 Immusoft Corp
14.3.14 LFB SA
14.3.15 mAbxience SA
